Ameritas Advisory Services’s Pacific Biosciences PACB Stock Holding History

Ameritas Advisory Services’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$517	Buy	+308	New	+$448	﹤0.01%	1841

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ameritas Advisory Services's PACB Position: Q2 2026 in Review

Ameritas Advisory Services opened a new position in Pacific Biosciences (PACB) in Q2 2026: 308 shares worth $517. The stake represents ﹤0.01% of the portfolio and ranks #1841 among its holdings.

223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Ameritas Advisory Services held 308 shares of Pacific Biosciences worth $517 as of Q2 2026.
Pacific Biosciences was a new Ameritas Advisory Services position in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q2 2026, its #1841 holding.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.